Biofrontera Gains FDA Approval for Ameluz in Basal Cell Carcinoma
WOBURN, Mass. — September 14, 2026 Biofrontera Inc. announced that the U.S. Food and Drug Administration (FDA) has approved...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WOBURN, Mass. — September 14, 2026 Biofrontera Inc. announced that the U.S. Food and Drug Administration (FDA) has approved...
ROCKVILLE, Md. – May 8, 2026 AAVnerGene Inc. announced the launch of AAVone®2.1, the next-generation evolution of its proprietary...
YOKNEAM, Israel – May 8, 2026 Lumenis announced that its groundbreaking hair restoration platform FoLix™ has received the Hair...
LONDON, UK – January 7, 2026 — iSMART Developments Ltd., a UK-based innovator in LED light-based skincare, aesthetics, and...
